Results 51 to 60 of about 8,176 (156)

Chinese Registry on Transjugular Intrahepatic Portosystemic Shunts (CN‐TIPS): Protocol for a Registry‐Based, Prospective Prognostic Study

Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 160-169, June 2026.
CN‐TIPS is a nationwide, multicenter prospective registry that will enroll 10,000 adults with portal hypertension undergoing transjugular intrahepatic portosystemic shunt in China, integrating perioperative clinical and hemodynamic metrics with standardized imaging (including computational modeling in a dedicated subcohort) and multi‐omics biospecimens,
Yi Xiang, Yong Lv, Hongwei Zhou, Jianbo Zhao, Meng Niu, Jiacheng Liu, Guangchuan Wang, Qi Zhang, Weizhong Zhou, Beijia Yu, Jun Chi, Guo Han, Jiawei Zhang, Long Gao, Wenjing Liu, Zhang Zhang, Tianyu Liu, Wuhua Guo, He Zhao, Gao‐Jun Teng, Xiaolong Qi   +20 more
wiley   +1 more source

Bile Acids Improve the Antimicrobial Effect of Rifaximin [PDF]

, 2010
Diarrhea is one of the most common infirmities affecting international travelers, occurring in 20 to 50% of persons from industrialized countries visiting developing regions.
Elizabeth J. Dial, Herbert L. DuPont, Zhi-Dong Jiang, Charles Darkoh, Lenard M. Lichtenberger, Nadim Ajami   +5 more
core   +1 more source

Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 11, Page 1487-1494, June 2026.
This multicenter, observational study reveals distinct alterations in the microbial spectrum of spontaneous bacterial peritonitis (SBP) associated with proton pump inhibitor use. These results are especially relevant for guiding empiric antibiotic therapy of SBP.
Philip Kitchen, Sarah L. Schütte, Tammo L. Tergast, Benjamin Maasoumy, Leonie Braun, Ulrich vor dem Esche, Georg Häcker, Marcus M. Mücke, Marlene Reincke, Michael Schultheiss, Robert Thimme, Siegbert Rieg, Dominik Bettinger, Lukas Sturm   +13 more
wiley   +1 more source

Low dose rifaximin combined with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D: a randomized trial [PDF]

Rifaximin is FDA-approved for treatment of irritable bowel syndrome with diarrhea (IBS-D), but poor solubility may limit its efficacy against microbes in the mucus layer, e.g. Escherichia coli. Here we evaluate adding the mucolytic N-acetylcysteine (NAC)
Ali Rezaie, Gillian M. Barlow, Walter Morales, Stacy Weitsman, Juliana de Freitas Germano, Gabriela Leite, Mark Pimentel, Maritza Sanchez, Ruchi Mathur, Gonzalo Parodi, Sarah Ayyad, Maya L. Pimentel, Maria Jesus Villanueva-Millan   +12 more
core   +1 more source

Association between specialized nutrition support and 90‐day mortality relative to standard of care in malnourished adults with decompensated cirrhosis: A retrospective cohort study

Journal of Parenteral and Enteral Nutrition, Volume 50, Issue 4, Page 544-556, May 2026.
Abstract Background Malnutrition is common among patients with decompensated liver cirrhosis and linked to poor prognosis. Guidelines recommend intensified nutrition support e.g. parenteral nutrition, but evidence regarding safety and effectiveness is scarce. We aimed to investigate the impact of nutrition support, specifically parenteral nutrition, on
Katharina L. Hupa‐Breier, Laura Buttler, Claudia Seipt, Andrea Markowski, Marie Griemsmann, Tammo L. Tergast, Birgit Kaufmann, Hannah Rieland, Heiner Wedemeyer, Benjamin Maasoumy, Andrea Schneider   +10 more
wiley   +1 more source

Rifaximin for the treatment of small intestinal bacterial overgrowth (SIBO) [PDF]

, 2019
SIBO (Small Intestinal Bacterial Overgrowth) är ett tillstånd där tunntarmen koloniseras av bakterier som normalt finns i tjocktarmen. SIBO utvecklas när de normala homeostatiska mekanismerna som kontrollerar enteriska bakteriepopulationen störs.
Hashim Bashir, Nazdar
core   +2 more sources

Chitosan–Alginate Polyelectrolyte Systems: From Classical Release Models to the D‐PARMO Framework

Macromolecular Materials and Engineering, Volume 311, Issue 5, May 2026.
Classical empirical models fail to predict the dynamic in vivo behavior of chitosan‐alginate nanocarriers. Bridging this translational gap, the novel D‐PARMO framework replaces purely descriptive curve‐fitting with a mechanistically informed operational model.
Parastoo Rekab, Akeem Adeyemi Oladipo
wiley   +1 more source

POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN [PDF]

, 2008
Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin alpha and rifaximin beta, and a poorly crystalline form named rifaximin gamma, useful in the production of medicinal preparations containing rifaximin for oral and topical use ...
CAMPANA M., ROSINI, GOFFREDO, RIGHI, PAOLO, BRAGA, DARIO, CONFORTINI D., CANNATA V., VISCOMI G. C.   +6 more
core  

Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 5, May 2026.
We systematically summarized the etiologies, diagnostic approaches, and pathogenic mechanisms of liver fibrosis. Also, the therapeutic interventions for liver fibrosis were systematically classified into two main categories: etiological treatment and mechanism‐based antifibrotic therapies.
Jiaorong Qu, Wenqing Qin, Minghang Dong, Zhi Ma, Si Li, Runping Liu, Ranyun Chen, Changmeng Li, Xiaojiaoyang Li   +8 more
wiley   +1 more source

PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN [PDF]

, 2008
Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin alpha and rifaximin beta, and a poorly crystalline form named rifaximin gamma, useful in the production of medicinal preparations containing rifaximin for oral and topical use ...
CAMPANA M., ROSINI, GOFFREDO, RIGHI, PAOLO, BRAGA, DARIO, CONFORTINI D., CANNATA V., VISCOMI G. C.   +6 more
core